|Cost of disorders of the brain in Europe 2010|
A Gustavsson, M Svensson, F Jacobi, C Allgulander, J Alonso, E Beghi, ...
European neuropsychopharmacology 21 (10), 718-779, 2011
|Resources for mental health: scarcity, inequity, and inefficiency|
S Saxena, G Thornicroft, M Knapp, H Whiteford
The lancet 370 (9590), 878-889, 2007
|Financial cost of social exclusion: follow up study of antisocial children into adulthood|
S Scott, M Knapp, J Henderson, B Maughan
Bmj 323 (7306), 191, 2001
|Costing psychiatric interventions|
J Beecham, M Knapp
Measuring mental health needs 2, 200-224, 2001
|Costs of autism spectrum disorders in the United Kingdom and the United States|
AVS Buescher, Z Cidav, M Knapp, DS Mandell
JAMA pediatrics 168 (8), 721-728, 2014
|Defeating Alzheimer's disease and other dementias: a priority for European science and society|
B Winblad, P Amouyel, S Andrieu, C Ballard, C Brayne, H Brodaty, ...
The Lancet Neurology 15 (5), 455-532, 2016
|World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future|
M Prince, A Comas-Herrera, M Knapp, M Guerchet, M Karagiannidou
Alzheimer’s Disease International (ADI), 2016
|The effectiveness of supported employment for people with severe mental illness: a randomised controlled trial|
T Burns, J Catty, T Becker, RE Drake, A Fioritti, M Knapp, C Lauber, ...
The Lancet 370 (9593), 1146-1152, 2007
|Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology|
DS Baldwin, IM Anderson, DJ Nutt, B Bandelow, A Bond, JRT Davidson, ...
Journal of Psychopharmacology 19 (6), 567-596, 2005
|Poverty and mental disorders: breaking the cycle in low-income and middle-income countries|
C Lund, M De Silva, S Plagerson, S Cooper, D Chisholm, J Das, M Knapp, ...
The lancet 378 (9801), 1502-1514, 2011
|Donepezil and memantine for moderate-to-severe Alzheimer's disease|
R Howard, R McShane, J Lindesay, C Ritchie, A Baldwin, R Barber, ...
New England Journal of Medicine 366 (10), 893-903, 2012
|The global costs of schizophrenia|
M Knapp, R Mangalore, J Simon
Schizophrenia bulletin 30 (2), 279-293, 2004
|Cognitive remediation therapy in schizophrenia: randomised controlled trial|
T Wykes, C Reeder, S Landau, B Everitt, M Knapp, A Patel, R Romeo
The British journal of psychiatry 190 (5), 421-427, 2007
|Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial|
A Steventon, M Bardsley, J Billings, J Dixon, H Doll, S Hirani, M Cartwright, ...
Bmj 344, 2012
|Dementia UK: update|
M Prince, M Knapp, M Guerchet, P McCrone, M Prina, A Comas-Herrera, ...
Alzheimer’s Society 1014, 43-4, 2014
|Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology.|
SC Smith, DL Lamping, S Banerjee, R Harwood, B Foley, P Smith, ...
Health Technology Assessment (Winchester, England) 9 (10), 1-iv, 2005
|Training carers of stroke patients: randomised controlled trial|
L Kalra, A Evans, I Perez, A Melbourn, A Patel, M Knapp, N Donaldson
Bmj 328 (7448), 1099, 2004
|Paying the price: the cost of mental health care in England to 2026|
PR McCrone, S Dhanasiri, A Patel, M Knapp, S Lawton-Smith
King's Fund, 2008
M Knapp, M Prince, E Albanese, S Banerjee, S Dhanasiri, JL Fernandez, ...
London: Alzheimer’s Society 7, 2007
|Long-term conditions and mental health: the cost of co-morbidities|
C Naylor, M Parsonage, D McDaid, M Knapp, M Fossey, A Galea
The King's Fund, 2012